ANAB - ANAPTYSBIO, INC
64.67
2.660 4.113%
Share volume: 901,628
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$62.01
2.66
0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-05-2024 | 11-05-2024 | 02-27-2025 | 05-05-2025 | 08-06-2025 | 11-04-2025 | 03-03-2026 | |
| Total revenue | 7.179 M | 10.971 M | 30.017 M | 43.113 M | 27.771 M | 22.263 M | 76.320 M | 108.249 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 7.179 M | 10.971 M | 30.017 M | 43.113 M | 27.771 M | 22.263 M | 76.320 M | 108.249 M | |
| 52.82% | 173.60% | 43.63% | -35.59% | -19.83% | 242.81% | 41.84% | |||
| Operating expenses | 49.380 M | 51.292 M | 52.774 M | 52.783 M | 55.310 M | 48.433 M | 41.616 M | 41.348 M | |
| Selling general and admin | 12.338 M | 9.295 M | 10.562 M | 10.194 M | 14.130 M | 10.609 M | 10.209 M | 15.789 M | |
| Research and development | 37.042 M | 41.997 M | 42.212 M | 42.589 M | 41.180 M | 37.824 M | 31.407 M | 25.559 M | |
| Total expenses | 49.380 M | 51.292 M | 52.774 M | 52.783 M | 55.310 M | 48.433 M | 41.616 M | 41.348 M | |
| 3.87% | 2.89% | 0.02% | 4.79% | -12.43% | -14.08% | -0.64% | |||
| Operating income | -42.201 M | -40.321 M | -22.757 M | -9.670 M | -27.539 M | -26.170 M | 34.704 M | 66.901 M | |
| Ebit | -42.203 M | -40.321 M | -22.762 M | -9.649 M | -25.637 M | -22.639 M | 34.704 M | 66.898 M | |
| Pretax income | -43.936 M | -46.651 M | -32.851 M | -21.790 M | -39.285 M | -38.591 M | 15.113 M | 49.695 M | |
| 6.18% | -29.58% | -33.67% | 80.29% | -1.77% | -139.16% | 228.82% | |||
| Income tax | 0.000 | 9.000 K | 0.000 | 0.000 | 44.000 K | 39.000 K | 0.000 | 81.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -43.936 M | -46.660 M | -32.851 M | -21.784 M | -39.329 M | -38.630 M | 15.113 M | 49.614 M | |
| -6.20% | 29.59% | 33.69% | -80.54% | 1.78% | 139.12% | 228.29% |